The DOCA-salt hypertensive rat as a model of cardiovascular oxidative and inflammatory stress

Current Cardiology Reviews

Volumn 6, Issue 4, 2010, Pages 291-297

  Iyer, Abishek ^a   Chan, Vincent ^b   Brown, Lindsay ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

Cardiovascular remodelling; DOCA salt; Fibrosis; Hypertrophy; Inflammation; Oxidative stress

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; FREE RADICAL; REACTIVE OXYGEN METABOLITE; SODIUM CHLORIDE;

ARTICLE; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DISEASE MODEL; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RELIABILITY;

EID: 78651301410     PISSN: 1573403X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340310793566109     Document Type: Article

References (85)

1. Weber KT, Sun Y, Katwa LC. Wound healing followingmyocardial infarction. Clin Cardiol 1996; 19: 447-55.
2. Weber KT, Brilla CG, Cleland JG, et al. Cardioreparation and theconcept of modulating cardiovascular structure and function. BloodPress 1993; 2: 6-21.
3. Sun Y. Myocardial repair/remodelling following infarction: roles oflocal factors. Cardiovasc Res 2009; 81: 482-90.
4. Takimoto E, Kass DA. Role of oxidative stress in cardiachypertrophy and remodeling. Hypertension 2007; 49: 241-8.
5. Iyer A, Brown L. Is mycophenolate more than just an immunosuppressant?--An overview. Indian J Biochem Biophys 2009; 46: 25-30.
6. Li JM, Shah AM. Endothelial cell superoxide generation:regulation and relevance for cardiovascular pathophysiology. Am JPhysiol Regul Integr Comp Physiol 2004; 287: R1014-30.
7. Kobashigawa JA. Cardiac allograft vasculopathy in heart transplantpatients: pathologic and clinical aspects for angioplasty/stenting. JAm Coll Cardiol 2006; 48: 462-3.
8. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-52.
9. Iyer A, Fairlie DP, Prins JB, et al. Inflammatory lipid mediators inadipocyte function and obesity. Nat Rev Endocrinol 2010; 6: 71-82.
10. Haddad JJ. Redox regulation of pro-inflammatory cytokines andIkappaB-alpha/NF-kappaB nuclear translocation and activation. Biochem Biophys Res Commun 2002; 296: 847-56.
11. Sun Y, Zhang J, Lu L, et al. Aldosterone-induced inflammation inthe rat heart: role of oxidative stress. Am J Pathol 2002; 161: 1773-81.
12. Mallat Z, Philip I, Lebret M, et al. Elevated levels of 8-isoprostaglandinF2alpha in pericardial fluid of patients with heartfailure: a potential role for in vivo oxidant stress in ventriculardilatation and progression to heart failure. Circulation 1998; 97: 1536-9.
13. Dworakowski R, Anilkumar N, Zhang M, et al. Redox signallinginvolving NADPH oxidase-derived reactive oxygen species. Biochem Soc Trans 2006; 34: 960-4.
14. Lum H, Roebuck KA. Oxidant stress and endothelial celldysfunction. Am J Physiol Cell Physiol 2001; 280: C719-41.
15. Clapp BR, Hingorani AD, Kharbanda RK, et al. Inflammationinducedendothelial dysfunction involves reduced nitric oxidebioavailability and increased oxidant stress. Cardiovasc Res 2004; 64: 172-8.
16. Kotlyar E, Vita JA, Winter MR, et al. The relationship betweenaldosterone, oxidative stress, and inflammation in chronic, stablehuman heart failure. J Card Fail 2006; 12: 122-7.
17. Doggrell SA, Brown L. Rat models of hypertension, cardiachypertrophy and failure. Cardiovasc Res 1998; 39: 89-105.
18. Selye H, Hall CE, Rowley EM. Malignant hypertension producedby treatment with desoxycorticosterone acetate and sodiumchloride. Can Med Assoc J 1943; 49: 88-92.
19. Gavras H, Brunner HR, Laragh JH, et al. Malignant hypertensionresulting from deoxycorticosterone acetate and salt excess: role ofrenin and sodium in vascular changes. Circ Res 1975; 36: 300-9.
20. de Champlain J, Krakoff L, Axelrod J. Interrelationships of sodiumintake, hypertension, and norepinephrine storage in the rat. CircRes 1969; 24: 75-92.
21. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120: 893-901.
22. de Champlain J, Krakoff LR, Axelrod J. Catecholamine metabolismin experimental hypertension in the rat. Circ Res 1967; 20: 136-45.
23. Molteni A, Nickerson PA, Latta J, et al. Development ofhypertension in rats maintained on a sodium deficient diet andbearing a mammotropic tumor (MtTF4). Virchows Arch B CellPathol 1975; 21: 191-203.
24. Brown L, Duce B, Miric G, et al. Reversal of cardiac fibrosis indeoxycorticosterone acetate-salt hypertensive rats by inhibition ofthe renin-angiotensin system. J Am Soc Nephrol 1999; 10: S143-8.
25. Hartner A, Klanke B, Cordasic N, et al. Statin treatment reducesglomerular inflammation and podocyte damage in ratdeoxycorticosterone-acetate-salt hypertension. J Hypertens 2009; 27: 376-85.
26. Klanke B, Cordasic N, Hartner A, et al. Blood pressure versusdirect mineralocorticoid effects on kidney inflammation andfibrosis in DOCA-salt hypertension. Nephrol Dial Transplant 2008; 23: 3456-63.
27. Iyer A, Fenning A, Lim J, et al. Antifibrotic activity of an inhibitorof histone deacetylases in DOCA-salt hypertensive rats. Br JPharmacol 2010; 159: 1408-17.
28. O'Brien D, Chunduri P, Iyer A, et al. L-carnitine attenuates cardiacremodelling rather than vascular remodelling in deoxycorticosteroneacetate-salt hypertensive rats. Basic Clin PharmacolToxicol 2010; 106: 296-301.
29. Iyer A, Brown L. Fermented wheat germ extract (Avemar) in thetreatment of cardiac remodeling and metabolic symptoms in rats. Evid Based Complement Alternat Med 2009;doi:10.1093/ecam/nep090.
30. Loch D, Hoey A, Morisseau C, et al. Prevention of hypertension inDOCA-salt rats by an inhibitor of soluble epoxide hydrolase. CellBiochem Biophys 2007; 47: 87-98.
31. Loch D, Levick S, Hoey A, et al. Rosuvastatin attenuateshypertension-induced cardiovascular remodeling without affectingblood pressure in DOCA-salt hypertensive rats. J CardiovascPharmacol 2006; 47: 396-404.
32. Chan V, Hoey A, Brown L. Improved cardiovascular function withaminoguanidine in DOCA-salt hypertensive rats. Br J Pharmacol 2006; 148: 902-8.
33. Levick S, Fenning A, Brown L. Increased calcium influx mediatesincreased cardiac stiffness in hyperthyroid rats. Cell BiochemBiophys 2005; 43: 53-60.
34. Fenning A, Harrison G, Rose'meyer R, et al. L-Arginine attenuatescardiovascular impairment in DOCA-salt hypertensive rats. Am JPhysiol Heart Circ Physiol 2005; 289: H1408-16.
35. Allan A, Fenning A, Levick S, et al. Reversal of cardiac dysfunctionby selective ET-A receptor antagonism. Br J Pharmacol 2005; 146: 846-53.
36. Loch D, Hoey A, Brown, L. Attenuation of cardiovascularremodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat. Clin Exp Hypertens 2006; 28: 475-88.
37. Mirkovic S, Seymour AM, Fenning A, et al. Attenuation of cardiacfibrosis by pirfenidone and amiloride in DOCA-salt hypertensiverats. Br J Pharmacol 2002; 135: 961-8.
38. Robert V, Van Thiem N, Cheav SL, et al. Increased cardiac types Iand III collagen mRNAs in aldosterone-salt hypertension. Hypertension 1994; 24: 30-6.
39. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis inDOCA-salt hypertensive rats: effect of endothelin ET(A) receptorantagonism. Circulation 2001; 16: 319-24.
40. Ammarguellat FZ, Gannon PO, Amiri F, et al. Fibrosis, matrixmetalloproteinases, and inflammation in the heart of DOCA-salthypertensive rats: role of ET(A) receptors. Hypertension 2002; 39: 679-84.
41. Fujisawa G, Dilley R, Fullerton MJ, et al. Experimental cardiacfibrosis: differential time course of responses to mineralocorticoidsaltadministration. Endocrinology 2001; 142: 3625-31.
42. Deng LY, Schiffrin EL. Effects of endothelin on resistance arteriesof DOCA-salt hypertensive rats. Am J Physiol 1992; 262: H1782-7.
43. Nunes VW, Fortes ZB, Nigro D, et al. Influence of enalapril on theendothelial function of DOCA-salt hypertensive rats. GenPharmacol 2000; 34: 117-25.
44. Pu Q, Touyz RM, Schiffrin EL. Comparison of angiotensinconvertingenzyme (ACE), neutral endopeptidase (NEP) and dualACE/NEP inhibition on blood pressure and resistance arteries ofdeoxycorticosterone acetate-salt hypertensive rats. J Hypertens 2002; 20: 899-907.
45. Somers MJ, Mavromatis K, Galis ZS, et al. Vascular superoxideproduction and vasomotor function in hypertension induced bydeoxycorticosterone acetate-salt. Circulation 2000; 11: 1722-8.
46. Kaplan NM. The current epidemic of primary aldosteronism:causes and consequences. J Hypertens 2004; 22: 863-9.
47. Tomaschitz A, Pilz S, Ritz E, et al. Aldosterone and arterialhypertension. Nat Rev Endocrinol 2010; 6: 83-93.
48. Iwashima F, Yoshimoto T, Minami I, et al. Aldosterone inducessuperoxide generation via Rac1 activation in endothelial cells. Endocrinology 2008; 149: 1009-14.
49. Selemidis S, Sobey CG, Wingler K, et al. NADPH oxidases in thevasculature: molecular features, roles in disease andpharmacological inhibition. Pharmacol Ther 2008; 120: 254-91.
50. Nediani C, Brochi E, Giordano C, et al. NADPH oxidasedependentredox signaling in human heart failure: relationshipbetween the left and right ventricle. J Mol Cell Cardiol 2007; 42: 826-34.
51. Cao X, Dai X, Parker LM, et al. Differential regulation of NADPHoxidase in sympathetic and sensory ganglia in deoxycorticosteroneacetate salt hypertension. Hypertension 2007; 50: 663-71.
52. Wilcox CS. Oxidative stress and nitric oxide deficiency in thekidney: a critical link to hypertension? Am J Physiol Regul IntegrComp Physiol 2005; 289: R913-35.
53. Beswick RA, Dorrance AM, Leite R, et al. NADH/NADPHoxidase and enhanced superoxide production in the mineralocorticoidhypertensive rat. Hypertension 2001; 38: 1107-11.
54. Karam H, Heudes D, Hess P, et al. Respective role of humoralfactors and blood pressure in cardiac remodeling of DOCAhypertensive rats. Cardiovasc Res 1996; 31: 287-95.
55. Li L, Watts SW, Banes AK, et al. NADPH oxidase-derivedsuperoxide augments endothelin-1-induced venoconstriction inmineralocorticoid hypertension. Hypertension 2003; 42: 316-21.
56. Callera GE, Touyz RM, Teixeira SA, et al. ETA receptor blockadedecreases vascular superoxide generation in DOCA-salthypertension. Hypertension 2003; 42: 811-7.
57. Young M, Fullerton M, Dilley R, et al. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 1994; 93: 2578-83.
58. Day R, Larivière R, Schiffrin EL. In situ hybridization showsincreased endothelin-1 mRNA levels in endothelial cells of bloodvessels of deoxycorticosterone acetate-salt hypertensive rats. Am JHypertens 1995; 8: 294-300.
59. Larivière R, Day R, Schiffrin EL. Increased expression ofendothelin-1 gene in blood vessels of deoxycorticosterone acetatesalthypertensive rats. Hypertension 1993; 21: 916-20.
60. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelinantagonist on vascular remodeling in deoxycorticosterone acetatesalthypertensive rats. Evidence for a role of endothelin in vascularhypertrophy. Hypertension 1994; 24: 183-8.
61. Fernandes S, Bruneval P, Hagege A, et al. Chronic V2 vasopressinreceptor stimulation increases basal blood pressure and exacerbatesdeoxycorticosterone acetate-salt hypertension. Endocrinology 2002; 143: 2759-66.
62. Park J, Galligan JJ, Fink GD, Swain GM. Alterations insympathetic neuroeffector transmission to mesenteric arteries butnot veins in DOCA-salt hypertension. Auton Neurosci 2010; 152: 11-20.
63. Hara K, Kobayashi N, Watanabe S, et al. Effects of quinapril onexpression of eNOS, ACE, and AT1 receptor in deoxycorticosterone acetate-salt hypertensive rats. Am J Hypertens 2001; 14: 321-30.
64. Schenk J, McNeill JH. The pathogenesis of DOCA-salt hypertension. J Pharmacol Toxicol Methods 1992; 27: 161-70.
65. Abrams JM, Osborn JW. A role for benzamil-sensitive proteins ofthe central nervous system in the pathogenesis of salt-dependenthypertension. Clin Exp Pharmacol Physiol 2008; 35: 687-94.
66. Jaquet V, Scapozza L, Clark RA, et al. Small-molecule NOXinhibitors:reactive oxygen species-generating NADPH oxidases astherapeutic targets. Antioxid Redox Signal 2009; 11: 2535-52.
67. Beswick RA, Zhang H, Marable D, et al. Long-term antioxidantadministration attenuates mineralocorticoid hypertension and renalinflammatory response. Hypertension 2001; 37: 781-6.
68. Nakano D, Kurumazuka D, Nagai Y, et al. Dietary sesaminsuppresses aortic NADPH oxidase in DOCA salt hypertensive rats. Clin Exp Pharmacol Physiol 2008; 35: 324-6.
69. Viel EC, Benkirane K, Javeshghani D, et al. Xanthine oxidase andmitochondria contribute to vascular superoxide anion generation inDOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 2008; 295: H281-8.
70. Paik DC, Dillon J, Galicia E, et al. The nitrite/collagen reaction:non-enzymatic nitration as a model system for age-related damage. Connect Tissue Res 2001; 42: 111-22.
71. Xu H, Fink GD, Galligan JJ. Tempol lowers blood pressure andsympathetic nerve activity but not vascular O2- in DOCA-salt rats. Hypertension 2004; 43: 329-34.
72. de Lorgeril M, Salen P. Selenium and antioxidant defenses asmajor mediators in the development of chronic heart failure. HeartFail Rev 2006; 11: 13-7.
73. Danesi F, Malaguti M, Nunzio MD, et al. Counteraction ofadriamycin-induced oxidative damage in rat heart by seleniumdietary supplementation. J Agric Food Chem 2006; 54: 1203-8.
74. Kroon PA, Iyer A, Chunduri P, et al. The cardiovascular nutrapharmacologyof resveratrol: pharmacokinetics, molecular mechanismsand therapeutic potential. Curr Med Chem 2010; 17: 2442-55.
75. Jadhav A, Torlakovic E, Ndisang JF. Hemin therapy attenuateskidney injury in deoxycorticosterone acetate-salt hypertensive rats. Am J Physiol Renal Physiol 2009; 296: F521-34.
76. Seifi B, Kadkhodaee M, Karimian SM, et al. Evaluation of renaloxidative stress in the development of DOCA-salt inducedhypertension and its renal damage. Clin Exp Hypertens 2010; 32: 90-7.
77. Takaoka M, Kobayashi Y, Yuba M, et al. Effects of alpha-lipoicacid on deoxycorticosterone acetate-salt-induced hypertension inrats. Eur J Pharmacol 2001; 424: 121-9.
78. Ishimaru K, Ueno H, Kagitani S, et al. Fasudil attenuatesmyocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensiverats. J Cardiovasc Pharmacol 2007; 50: 187-94.
79. Kagitani S, Ueno H, Hirade S, et al. Tranilast attenuates myocardialfibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats. JHypertens 2004; 22: 1007-15.
80. Wu R, Laplante MA, De Champlain J. Prevention of angiotensinII-induced hypertension, cardiovascular hypertrophy and oxidativestress by acetylsalicylic acid in rats. J Hypertens 2004; 22: 793-801.
81. Monk PN, Scola AM, Madala P, et al. Function, structure andtherapeutic potential of complement C5a receptors. Br J Pharmacol 2007; 152: 429-48.
82. Halili MA, Andrews MR, Sweet MJ, et al. Histone deacetylaseinhibitors in inflammatory disease. Curr Top Med Chem 2009; 9: 309-19.
83. Ogata T, Miyauchi T, Sakai S, et al. Myocardial fibrosis anddiastolic dysfunction in deoxycorticosterone acetate-salt hypertensiverats is ameliorated by the peroxisome proliferator-activatedreceptor-alpha activator fenofibrate, partly by suppressinginflammatory responses associated with the nuclear factor-kappa-Bpathway. J Am Coll Cardiol 2004; 43: 1481-8.
84. Bae EH, Kim IJ, Ma SK, et al. Rosiglitazone prevents theprogression of renal injury in DOCA-salt hypertensive rats. Hypertens Res 2010; 33: 255-62.
85. Elmarakby AA, Quigley JE, Imig JD, et al. TNF-alpha inhibitionreduces renal injury in DOCA-salt hypertensive rats. Am J PhysiolRegul Integr Comp Physiol 2008; 294: R76-83.